Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Argenx Se ADR (NQ: ARGX )

614.59 +7.43 (+1.22%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Argenx Se ADR

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Amicus Therapeutics Stock Scores Healthy Relative Strength Upgrade
On Thursday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, from 78 to 81. 
Via Investor's Business Daily
The Latest Analyst Ratings for argenx
Via Benzinga
argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023
From argenx SE
Via GlobeNewswire
argenx announces full exercise of underwriters’ option to purchase additional ADSs
From argenx SE
Via GlobeNewswire
argenx raises $1.1 billion in gross proceeds in a global offering
From argenx SE
Via GlobeNewswire
If You Invested $100 In This Stock 5 Years Ago, You Would Have $500 Today
Via Benzinga
Why Argenx Stock Is on Fire Today
A major clinical win is boosting the drugmaker's shares today. 
Via The Motley Fool
Why Is Argenx (ARGX) Stock Up 27% Today?
Argenx (ARGX) stock is climbing higher on Monday following the release of data from a Phase 1 clinical trial of VYVGART Hytrulo. 
Via InvestorPlace
Immunovant's FcRn Strategy Gains Momentum: Analysts View ADHERE Study as De-Risking Factor for CIDP Clinical Development
Monday, Argenx SE (NASDAQ: ARGX) reported topline results from the ADHERE study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with chronic inflammatory demyelinating... 
Via Benzinga
argenx announces launch of proposed global offering
From argenx SE
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
argenx SE (NASDAQ: ARGX) Leading the Way in Monday Trading Based on Percentage Gain
Via Investor Brand Network
Argenx Catapults 27% To Record High As It Edges Closer To A New Multibillion-Dollar Market
Vyvgart is already approved in multiple diseases. But Argenx isn't stopping there. 
Via Investor's Business Daily
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived... 
Via Benzinga
You Can't Afford to Miss Monday's 2 Nasdaq Biotech Stock Movers
Big gains are afoot even as the markets prepare for a flat open. 
Via The Motley Fool
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why BYND Cannasoft Enterprises Shares Are Trading Lower By 40%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Why Is BYND Cannasoft Enterprise (BCAN) Stock Down 46% Today?
BYND Cannasoft Enterprise (BCAN) stock is dropping on Monday after the company announced an underwritten stock offering. 
Via InvestorPlace
Why Are Argenx Shares Trading Higher Today?
Argenx SE (NASDAQ: ARGX) reported topline results from the ADHERE study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with chronic inflammatory  
Via Benzinga
Why Is Quoin Pharmaceuticals (QNRX) Stock Down 90% Today?
Quoin Pharmaceuticals (QNRX) stock is taking a massive beating on Monday as the company prepares for an ADS ratio change. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday! 
Via InvestorPlace
Activision Blizzard, Argenx And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures traded mixed this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
From Zai Lab Limited
Via GlobeNewswire
argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
This Emerging Market Could Be the Next Big Thing in Biotech
Medicines to treat the many symptoms of long COVID are in high demand already. 
Via The Motley Fool
Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration
F-star Therapeutics formed a license agreement with Takeda to develop Fcab domains aimed at undisclosed immuno-oncology targets. Also, Brii Bio signed a global license to an HBV immunotherapeutic... 
Via Talk Markets
argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
From argenx SE
Via GlobeNewswire
Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
From Zai Lab Limited
Via GlobeNewswire
FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults
The FDA approved UCB SA's (OTC: UCBJF) (OTC: UCBJY) Rystiggo (rozanolixizumab-noli) for generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or... 
Via Benzinga
AstraZeneca Seeks Expanded Use For Soliris As First Targeted Therapy For Pediatric Patients With Autoimmune Neuromuscular Disease
The European Union has reco 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.